LONDON — A major shakeup in how the benefits of medicines are assessed in Europe is looming, and developers of treatments like gene therapies are already arguing that what they see as flaws in the new system could entrench the issues they’ve had getting their products to patients.
Starting next year, there will be a new, continent-level review of a drug’s effectiveness compared to what else is on the market. It’s a wonky policy shift in the arcane world of HTA — that is, “health technology assessment,” which is when authorities review a new drug and determine what price is cost-effective — that has drugmakers big and small racing to adapt. Some have even been running dress rehearsals of the new procedures.
“This is probably the biggest change to HTA in the last 20 to 30 years,” James Ryan, a health economist at AstraZeneca, said at a recent industry conference.
Click this link for the original source of this article.
Author: Andrew Joseph
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.